Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

90Y Ibritumomab Tiuxetan

90Y Ibritumomab Tiuxetan ▴ 90Yttrium (90Y) ibritumomab tiuxetan is a radiolabeled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumor activity as a result of emission of β particles. It is administered as part of a therapeutic regimen which includes rituximab, a monoclonal antibody which produces antibody-dependent cell-and complement-mediated cytotoxicity. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/90y-ibritumomab-tiuxetan-sQrg0LyT1q
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201050-00004
Publisher site
See Article on Publisher Site

Abstract

▴ 90Yttrium (90Y) ibritumomab tiuxetan is a radiolabeled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumor activity as a result of emission of β particles. It is administered as part of a therapeutic regimen which includes rituximab, a monoclonal antibody which produces antibody-dependent cell-and complement-mediated cytotoxicity.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References